|
|
Medical Analyses
- Part I
To view some articles below, you will need Adobe
Acrobat Reader
Articles on Cannabis
and Perspectives
- Devane (1994).
Current Awareness. New Dawn of Cannabinoid Pharmacology.
February, 1994. Trends in Pharmacological Sciences.
- Dreher, Melanie
C., PhD; Kevin Nugent, PhD; and Rebekah Hudgins, MA (1994).Prenatal
Marijuana Exposure and Neonatal Outcomes in Jamaica: An Ethnographic
Study Pediatrics, February 1994, Volume 93, Number 2, pp. 254-260.
American Academy of Pediatrics
- Doblin & Kleiman
(1991) Marijuana
as Antiemetic Medicine: A Survey of Oncologists' Experiences and Attitudes.
Journal of Clinical Oncology, vol 9, no 7 (July), 1991: pp 1314-1319.
- Grinspoon, Lester
(ed.) (1987) Marijuana.
The Harvard Medical School Mental Health Letter. Volume 4, Number
5, November 1987.
- Husain, S and
Kahn, I (1985) An update on cannabis
research. . World Health Organization, Geneva, Switzerland. 1985/01/01
- Johnson & Gerstein
(1998) Inition
of Use of Alcohol, Cigarettes, Marijuana, Cocaine, and Other Substances
in US Birth Cohorts since 1919. American Journal of Public Health,
Jan 1998, vol 88 No 1.
-
- Liskow, Barry
I. (1973) Review of Nahas' book: Marijuana: Deceptive
Weed. JAMA, p. 630, April 1973 vol 224 No 5.
- Mathre, Mary
Lynn (1997). Medicinal Use of Marijuana. AJN,
November 1997, vol 97, no 11.
- Nahas, G. G.
(1985) Critique of a study on ganja in Jamaica.
United Nations Office for Drug Control and Crime Prevention. <http://www.undcp.org/bulletin/bulletin_1985-01-01_4_page004.html>
- Schaeffer, Jeffrey
et. al. (1981). Cognition and Long-Term
Use of Ganja (Cannabis) Reprint Series 24 July 1981, Volume 213,
pp. 465-466 SCIENCE
- Schwartz, Richard
et.al (1997) Marijuana
to Prevent Nausea and Vomiting in Cancer Patients: A Survey of Clinical
Oncologists. Southern Medical Journal. February 1997, vol 90,
No 2.
- Silverstein
& Lessin (1974) Normal Skin Test Responses in
Chronic Marijuana Users. Science, vol 186, 740, 1974.
- Skidmore et.al
(1997) Marijuana
as Medicine (letters). AJN, May 1998, vol 98, No 5.
- US
National Drug Strategy Monograph Series No. 25: The health and
psychological consequences of cannabis use (chapters 1 to 9)
- Zimmer, Lynn
(1995) Exposing Marijuana Myths: A Review of
the Scientific Evidence. The Lindesmith Center, 1995.
- Zinberg, Norman
(1976) Review,
Marijuana. Psychology Today, December 1976.
Articles on Cannabis
and Apoptosis and Proliferation
Articles on Cannabis
and Receptors
Agonists Antagonists
- Bayewitch et.al
(1996). (-)-Delta9-tetrahydrocannabinol antagonizes
the peripheral cannabinoid receptor-mediated inhibition of adenylyl
cyclase. J. Biol. Chemistry. Vol 271, No 17, April 26, pp. 9902-9905,
1996.
- Bonhaus et.al
(1998). Dual activation and inhibition of adenylyl
cyclase by cannabinoid receptor agonists: evidence for agonistic-specific
trafficking of intracellular responses. J.Pharmacology and Experimental
Therapeutics, Vol 287, No 3, pp. 884-888, 1998.
- Brodkin et.al
(1997). SR141716A Antagonizes the disruptive effects
of cannabinoid ligands on learning in rats. J. Pharmacology and
Experimental Therapeutics 282:1526-1532, 1997/
- Chapman et.al
(1998). N-Acylethanolamines: Formation and molecular
composition of a new class of plant lipids. Plant Physiol. (1998)
116:1163-1168.
- Devane et.al
(1992) Isolation
and structure of a brain constituent that binds to the cannabinoid
receptor. Science, Vol 258, December 1992
- Edgemond et.al
(1998) Synthesis and characterization of diazomethylarachidonyl
ketone: an irreversible inhibitor of N-arachidonylethanolamine amidohydrolase.
J. Pharmacol. Exp. Ther. 286:184-190, 1998.
- Felder et.al
(1992). Cannabinoid
agonists stimulate both receptor and non-receptor-mediated signal
transduction pathways in cells transfected with and expressing cannabinoid
receptor clones. Mol. Pharmacology, 42: 838-845, 1992.
- Felder et.al
(1998) LY320135, a novel cannabinoid CB1
receptor antagonist, unmasks coupling of the CB1 receptor to stimulation
of cAMP accumulation. J. Pharmacol. Exp. Ther., 284:291-297, 1998.
- Fellermeier
et.al (1998). Prenylation of olivetolate
by a hemp transferase yields cannabigerolic acid, the precursor of
tetrahydrocannabinol. FEBS Letters 427 (1998) 283-285.
- Fride & Mechoulam
(1993). Pharmacological activity of the cannabinoid
receptor agonist, anandamide, a brain constituent. Eur. J. Pharmacology,
231 (1993) 313-314.
- Griffin et.al
(1998). Evaluation of cannabinoid receptor agonists
and antagonists using the guanosine-5'-0-(3-[35S]thio)-triphosphate
binding assay in rat cerebellar membranes. J. Pharmacol. Exp.
Ther. 285:553-560, 1998.
- Mallet et.al
(1998) The cannabinoid CB1 receptor antagonist SR141716A
attenuates the memory impairment produced by delta9-tetrahydrocannabinol.
Psychopharmacology (1998) 140:11-19.
- Pop & Brewster
(1997) Dimerization of dexanabinol by hydrogen bonding
acounts for its hydrophobic character. Int. J. Quantum Chemistry,
vol 65, 1057-1064 (1997).
- Rinaldi-Carmona
et.al (1998) SR 144528, the first potent and
selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol.
Exp. Ther., 284:644-650, 1998.
- Smith et.al
(1994). The
pharmacological activity of anandamine, a putative endogenous cannabinoid,
in mice. J. Pharmacol. Exp. Ther., vol 270, No 1, pp. 219-227.
- Stella et.al
(1997). A
second endogenous cannabinoid that modulates long-term potentiation.
Nature, Vol 388, August 1997.
- Thomas et.al
(1998). Comparative receptor binding analyses of
cannabinoid agonists and antagonists. J. Pharmacol. Exp. Ther.,
285:285-292, 1998.
- Welch et.al
(1998). Differential Blockade of the antinociceptive
effects of centrally administered cannabinoids by SR141716A. J.
Pharmacol. Exp. Ther., 286:1301-1308.
- Wiley et.al
(1998). Structure-activity relationships of indole-
and pyrrole-derived cannabinoids. J. Pharmaco. Exp. Ther., 285:995-1004,
1998.
- Xie et al.
(1996). The conformational properties of the
highly selective cannabinoid receptor ligand CP-99,540. JBiolChem,
vol 271, No 18, May 3, 1996, pp. 10640-10647.
Endogenous Agonists
- Adams et.al
(1998). Assessment of anandamine interaction
with the cannabinoid brain receptor: SR 141716A antagonism studies
in mice and autoradiographic analysis of receptor binding in rat brain.
J. Pharmacol. Exp. Ther., 284:1209-1217, 1998.
- Beltramo et.al
(1997). Functional role of high-affinity anandamide
transport, as revealed by selective inhibition. Science, Vol 277,
22 Aug 1997.
- Bisogno et.al
(1997). Biosynthesis, release and degradation
of the novel endogenous cannabimimetic metabolite 2-arachidonoylglycerol
in mouse neuroblastoma cells. Biochem. J. 322:671-677, 1997.
- Cadas et.al
(1996). Biosynthesis of an endogenous cannabinoid
precursor in neurons and its control by calcium and cAMP. J. Neuroscience,
June 15, 1996, 16(12):3934-3942.
- Cadas et.al
(1997). Occurrence
and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl
phosphatidylethanolamine, in rat brain. J. Neuroscience, February
15, 1997, 17(4):1226-1242.
- Compton et.al
(1997). The effect of the enzyme inhibitor phenylmethylsulfonyl
fluoride on the pharmacological effect of anandamide in the mouse
model of cannabimimetic activity. J. Pharmacol. Exp. Ther., 283:1138-1143,
1997.
- Deutsch et.al
(1997). Production and physiological actions
of anandamide in the vasculature of the rat kidney. J. Clin. Invest.
Vol 100, No 6, September 1997, 1538-1546.
- Di Marzo et.al
(1996). Biosynthesis
of anandamide and related acylethanolamides in mouse J774 macrophages
and N18 neuroblastoma cells. Biochem. J. (1996) 316, 977-984.
- Edgemond et.al
(1998a) Human platelets and polymorphonuclear
leukocytes synthesize oxygenated derivatives of arachidonylethanolamide
(anandamide). Mol. Pharmacology, 54:180-188 (1998).
- Giuffrida &
Piomelli (1998). Isotope dilution GC/MS determination
of anandamide and other fatty acylethanolamides in rat blood plasma.
FEBS Letters, 422 (1998) 373-376.
- Goparahu et.al
(1998). Anandamide amidohydrolase reacting with
2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS
Letters, 422 (1998), 69-73.
- Kempe et.al
(1996). Isotope dilution mass spectrometric measurements
indicate that arachidonylethanolamide, the proposed endogenous ligand
of the cannabinoid receptor, accumulates in rat brain tissue post
morten but is contained at low levels in or is absent from fresh tissue.
J. Biol. Chemistry, Vol 271, No 29, July 19, pp. 17287-17295.
- Kondo et.al
(1998). 2-Arachidonoylglycerol, an endogenous cannabinoid
receptor agonist: identification as one of the major species of monoacylglycerols
in various rat tissues, and evidence for its generation through Ca2+-dependent
and -independen mechanisms. FEBS Letters, 429 (1998) 152-156.
- Sugiura et.al
(1996). Transacylase-mediated and phosphodiesterase-mediated
synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor
ligand, in rat brain microsomes. Eur. J. Biochemistry, 240, 53-62
(1996).
- Ueda et.al
(1995). Partial purification and characterization of
the porcine brain enzyme hydrolyzing and synthesizing anandamide.
J. Biol. Chemistry, Vol 270, No 40, October 6, 1995, pp. 23823-23827.
- Willoughby et.al
(1997). The biodisposition and metabolism
of anandamide in mice. J. Pharmacol. Exp. Ther. 282:243-247, 1997.
Receptors
- Abood & Martin
(1996). Molecular
neurobiology of the cannabinoid receptor. Int. Rev. Neurobiology,
vol 39(?), pp. 197-221.
- Breivogel et.al
(1997). Regional differences in cannabinoid
receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther.
282:1632-1642, 1997.
- Di Marzo et.al
(1998). Interactions between synthetic vanilloids
and the endogenous cannabinoid system. FEBS Letters 436 (1998)
449-454.
- Facci et.al
(1995) Mast
cells express a peripheral cannabinoid receptor with differemtial
sensitivity to anandamine and palmitoylethanolamide. Proc. Natl.
Acad. Sci. Vol 92, pp. 3376-3380. April 1995, Pharmacology.
- Garcia et.al
(1998) Protein kinase C disrupts cannabinoid
actions by phosphorylation of the CB1 cannabinoid receptor. J.
Neuroscience, April 15, 1998, 18(8):2834-2841.
- Gifford et.al
(1999). Large receptor reserve for cannabinoid
actions in the central nervous system. J. Pharmacol. Exp. Ther.
288:478-483, 1999.
- Glass & Felder
(1997) Concurrent stimulation of cannabinoid
CB1 and dopamine D2 receptors augments cAMP accumulation in striatal
neurons: evidence for a Gs linkage to the CB1 receptor. J. Neuroscience,
July 15, 1997, 17(14):5327-5333.
- Howlett et
al. (1990) Classical
and nonclassical cannabinoids: mechanisms of action-brain binding.
NIDA Res Monogr Ser 1990;96:100-110.
- Howlett et.al
(1998) Characterization of CB1 cannabinoid
receptors using receptor peptide fragments and site-directed antibodies.
Mol. Pharmacology 53:504-510 (1998).
- Howlett et.al
(1988). Nonclassical
cannabinoid analgetics inhibit adenylate cyclase: development of a
cannabinoid receptor model. Mol. Pharmacology, 33: 297-302.
- Matsuda et.al
(1990) Structure
of a cannabinoid receptor and functional expression of the cloned
cDNA. Nature, Vol 346, 9 August 1990.
- Romero et.al
(1997). Atypical location of cannabinoid receptors
in white matter areas during rat brain development. Synapse 26:317-323
(1997).
- Romero et.al
(1998) Time-course of the cannabinoid receptor
down-regulation in the adult rat brain caused by repeated exposure
to delta9-tetrahydrocannabinol. Synapse 30: 298-308 (1998).
- Shire et.al
(1996) Structural features of the central
cannabinoid CB1 receptor involved in the binding of the specific CB1
antagonist SR141716A. J. Biol. Chemistry, Vol 271, No 12, March
22, 1996, pp. 6941-6946.
- Sim et.al
(1996) Effects
of chronic treatment with delta9-tetrahydrocannabinol on cannabinoid-stimulated
[35S]GTPgamaS autoradiography in rat brain. J. Neuroscience, December
15, 1996, 16(24):8057-8066.
- Tao & Abood
(1998) Mutation of a highly conserved aspartate
residue in the second transmembrane domain of the cannabinoid receptors,
CB1 and CB2, disrupts G-protein coupling. J. Pharmacol. Exp. Ther.
285:651-658, 1998.
Reviews
Articles on Cannabis
and Reproduction
Articles on Cannabis
and Synaptic Transmission
Top
|
